Dry And Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three vascular endothelial growth factor (VEGF) inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea. Roche’s Susvimo (ranibizumab port delivery system [PDS]), which launched in November 2021 in the United States, will also continue to attract a small patient share because of its less-frequent dosing regimen of once every six months. Additionally, we expect Roche / Chugai’s Vabysmo (faricimab), which launched in the United States in February 2022, in the United Kingdom and Japan in May 2022, and in Germany in October 2022, to continue to experience strong uptake, driven by its new mechanism of action (MOA) and advantageous dosing regimen. More therapies for wet AMD are in the late-phase pipeline, including Regeneron / Bayer’s high-dose aflibercept and biosimilar agents. In contrast to the management of wet AMD, the management of dry AMD is limited; no prescription therapies are approved for this large subpopulation. However, in March 2023, Apellis’s pegcetacoplan launched as Syfovre in the United States, the first therapy approved for geographic atrophy (GA), and in December 2022, Astellas and Iveric Bio submitted a new drug application (NDA) for the C5 complement inhibitor Zimura, which will undergo an FDA review in August 2023.

Questions answered

• How will the wet AMD treatment algorithm change as new products launch?
• To what extent will novel therapies such as Roche’s faricimab capitalize on the need for therapies with longer dosing intervals?
• How will market dynamics be impacted by the launch of biosimilars of Lucentis and Eylea?
• How receptive are retinal specialists to novel gene therapy approaches and to emerging therapies for wet AMD and GA?
• What will be the impact of Outlook Therapeutics’ ONS-5010 on Avastin if it launches for wet AMD, particularly in the United States?

Content highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 25 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Total prevalence of late AMD, by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2031, segmented by brands / biosimilars and epidemiological subpopulations.

Emerging therapies: Phase 3 / PR: 7 drugs; Phase 2: 12 drugs; coverage of select Phase 1 products.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature updates in 2023 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.